Diabetic retinopathy

April 14, 2019

Ribonucleic acid-based combination therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MEG3, Epicatechin and Matrine (MEG3EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 14/April/2019,  6.23 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
April 12, 2019

Ribonucleic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MIAT, Epicatechin and Matrine (MIATEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018,  10.00 pm

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
January 17, 2019

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fasudil, Epicatechin and Matrine (FEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 17/January/2018, 11.41 pm

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
January 4, 2019

RNA-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  lncRNA TUG1, Epicatechin and Matrine (TUG1EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 12.04 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]